[Skip to Content]
[Skip to Content Landing]
April 2004

Oral Pentoxifylline vs Topical Betamethasone in Schamberg Disease: A Comparative Randomized Investigator-Blinded Parallel-Group Trial

Arch Dermatol. 2004;140(4):491-493. doi:10.1001/archderm.140.4.491

Previous uncontrolled studies have suggested that pentoxifylline could be useful in the treatment of Schamberg disease (progressive purpuric pigmented dermatosis, PPPD).1,2 The objective of this randomized, investigator-blinded trial was to compare the clinical efficacies of oral pentoxifylline (Trental; Aventis, Mumbai, India) sustained-release dragées, 400 mg thrice daily, and topical betamethasone dipropionate cream, 0.05% wt/wt (Diprovate; Croslands, Pune, India) thin-film application locally twice daily. Steroids, topical and systemic, are credited with providing limited benefits and are commonly used to treat this condition.3

First Page Preview View Large
First page PDF preview
First page PDF preview